Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)

Launched by BETTINA MITTENDORFER · Aug 22, 2024

Keywords

ClinConnect Summary

The clinical trial titled "Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity" is exploring how certain immune cells in fat tissue, called macrophages, are involved in weight gain and related health issues like diabetes and fatty liver disease. Researchers want to understand the differences in how these cells process fats in people with different body types—those who are lean and those who are obese. By studying these differences, they hope to find new ways to improve health in people struggling with obesity.

To participate in this study, individuals need to be between 18 and 70 years old and meet specific health criteria based on their weight and blood sugar levels. Participants will undergo a screening visit, followed by imaging tests to assess body composition, and an overnight stay where they will receive an intravenous infusion and have small samples taken from their muscle and fat tissue. This study is currently looking for volunteers, regardless of gender, who fit the eligibility requirements to help advance our understanding of obesity and its impact on health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria :
• • age: ≥18 but ≤70 years
• • not pregnant or breastfeeding
• • weight stable and sedentary before enrollment
• • no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity \[MAO\]-Type 2 Diabetes group)
• • no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)
• * participants must fulfil all of the following group-specific inclusion criteria below:
• Lean group:
• • Body mass index (BMI) ≥18.5 but \<25.0 kg/m2
• • Intrahepatic triglyceride (IHTG) content \<5%
• • fasting blood glucose concentration: \<100 mg/dl
• • blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl
• • Hemoglobin A1C (HbA1c) \<5.7 %
• Metabolically normal obesity (MNO) group:
• • BMI ≥30.0 but \<45.0 kg/m2
• • IHTG content \<5%
• • fasting blood glucose concentration: \<100 mg/dl
• • blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl
• • HbA1c \<5.7 %
• Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:
• • BMI ≥30.0 but \<45.0 kg/m2
• • IHTG content \>7.5%
• • fasting blood glucose concentration: ≥100 but \<126 mg/dl
• • blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but \<200 mg/dl
• • HbA1c: ≥5.7 but \<6.4 %
• MAO-type 2 diabetes group:
• • BMI ≥30.0 but \<45.0 kg/m2
• • clinical diagnosis of type 2 diabetes or fasting blood glucose concentration \>126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge\>200 mg/dl or HbA1c \>6.4 % without medication if not diagnosed and medically treated for diabetes
• Exclusion Criteria:
• • - Individuals that do not meet all inclusion Criterion